ENTELLUS MEDICAL, INC. (NASDAQ:ENTL) Files An 8-K Entry into a Material Definitive AgreementItem 1.01.
|
Exhibit No. |
Description |
| 2.1 | Agreement and Plan of Merger dated as of July6, 2017 among Entellus Medical, Inc., Stinger Merger Sub Inc., Spirox, Inc., and Fortis Advisors LLC, as the Equityholders Representative* |
| 10.1 | First Amendment to Loan and Security Agreement dated as of July13, 2017 among Oxford Finance LLC, the Lenders thereto, Entellus Medical, Inc., Entellus Intermediate Sub, Inc. and Spirox, Inc. |
| 10.2 | Form of Indemnification Agreement between Entellus Medical, Inc. and Each Director and Officer of Entellus Medical, Inc. |
| * | All exhibits and schedules to the Agreement and Plan of Merger have been omitted to Item601(b)(2) of Regulation S-K. Entellus will furnish the omitted exhibits and schedules to the SEC supplementally upon request by the SEC. |
to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Date: July14, 2017 | ENTELLUS MEDICAL, INC. |
| By: /s/ Robert S. White | |
|
Name: Robert S. White |
|
|
Title: President and Chief Executive Officer |
ENTELLUS MEDICAL, INC.
CURRENT REPORT ON FORM 8-K
EXHIBIT INDEX
|
Exhibit No. |
Description |
Method of Filing |
| 2.1 | Agreement and Plan of Merger dated as of July6, 2017 among Entellus Medical, Inc., Stinger Merger Sub Inc., Spirox, Inc., and Fortis Advisors LLC, as the Equityholders Representative* |
Incorporated by reference to Exhibit 2.1 to Entellus’s Current Report on Form 8-K filed with the SEC on July7, 2017 (File No. 001-36814) |
| 10.1 | First Amendment to Loan and Security Agreement dated as of July13, 2017 among Oxford Finance LLC, the Lenders thereto, Entellus Medical, Inc., Entellus Intermediate Sub, Inc. and Spirox, Inc. | Filed herewith |
| 10.2 | Form of Indemnification Agreement between Entellus Medical, Inc. and Each Director and Officer of Entellus Medical, Inc. | Filed herewith |
| * | All exhibits and schedules to the Agreement and Plan of Merger have been omitted ENTELLUS MEDICAL INC ExhibitEX-10.1 2 d410722dex101.htm EX-10.1 EX-10.1 Exhibit 10.1 FIRST AMENDMENT TO LOAN AND SECURITY AGREEMENT THIS FIRST AMENDMENT to Loan and Security Agreement (this “Amendment”) is entered into as of July 13,…To view the full exhibit click hereAbout ENTELLUS MEDICAL, INC. (NASDAQ:ENTL) Entellus Medical, Inc. is a medical technology company. The Company is focused on the design, development and commercialization of products for the minimally invasive treatment of patients who are suffering from chronic sinusitis. The Company’s XprESS family of products is used by ear, nose and throat (ENT) physicians to treat patients with symptomatic inflammation of the nasal sinuses by opening narrowed or obstructed sinus drainage pathways using balloon sinus dilation. The Company’s XprESS family of products is used to treat patients with inflammation of the frontal, ethmoid, sphenoid and maxillary sinuses. Its XprESS Multi-Sinus Dilation family of products consists of its XprESS Pro device, its XprESS LoProfile device and its XprESS Ultra device. The Company’s PathAssist tools provide ENT physicians with a way to confirm sinus location and XprESS device placement. Its FocESS Sinuscopes provide ENT physicians with a solution for endoscopic visualization during a sinus procedure. |
